Kura Oncology receives "outperform" and "overweight" ratings from Wedbush and Cantor Fitzgerald.

Kura Oncology (KURA) has received an "outperform" rating from Wedbush and a reaffirmed "overweight" rating from Cantor Fitzgerald. The biotech company focuses on developing treatments for various cancers. Both financial institutions express optimism about Kura Oncology's future prospects.

August 12, 2024
3 Articles